🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

A phenolic acid glyceride dimer isolated from Lilium brownii exerts neuroprotective effects in Parkinson's disease by modulating the p62-Keap1-Nrf2 signalling pathway.

PMID: 41620005 · DOI: 10.1016/j.ejphar.2026.178618 · European journal of pharmacology, 2026 · Yuxiao Feng, Hengyun Tian, Chengcheng Hui, Jiaqi Shi, Yongqi Song, Xuesu Sun, Hongqi Xie, Ping'an Li, Yanpo Si, Tao Guo
📄 Abstract

Lilium brownii is a plant that can be used for medicinal and food purposes. 1-O-p-coumaroyl-3-O-feruloyl glycerol (CF) is a phenolic acid glycerol dimer isolated from Lilium brownii. This study aims to evaluate the neuroprotective effects of CF and elucidate the possible molecular mechanisms underlying its neuroprotective effects through in vivo and in vitro models of Parkinson's disease. 1-methyl-4-phenylpyridinium ions (MPP Following CF administration, the apoptosis rate and reactive oxygen species (ROS) levels in PC12 cells were significantly reduced. CF markedly upregulated the expression of proteins including dopamine, tyrosine hydroxylase, brain-derived neurotrophic factor (BDNF), while simultaneously downregulating the expression of proteins such as α-synuclein. Molecular docking results demonstrated favorable affinity between CF and proteins including p62. This compound not only ameliorated motor and cognitive impairments in Parkinson's disease mice but also markedly increased neuronal numbers within the substantia nigra region of these animals. CF exerts a neuroprotective effect in Parkinson's disease by modulating the p62-Keap1-Nrf2 signalling pathway.

Confidence: 0.34 · 7 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
PC12 cells treated with MPP+
0.90
In vivo
Parkinson's disease mice
0.90
In silico
Molecular docking of CF with p62
0.90
Genetic association
0.00
Ex vivo
0.00
Animal model
Parkinson's disease mice
0.90
Diet/model
0.00
Клиника (11 полей)
Drug
1-O-p-coumaroyl-3-O-feruloyl glycerol
0.95
Indication
Parkinson's disease
0.95
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
False
0.90